AFP-Producing Gastric Hepatoid Adenocarcinoma Clinical Case Report

Shi-Yu Zhong authored a 2026 clinical case report detailing a 68-year-old male with AFP-producing gastric hepatoid adenocarcinoma. The report includes quantitative CT enhancement values (52 ± 3 HU arterial, 78 ± 5 HU portal, 85 ± 4 HU delayed) and a serum AFP level of 918.88 ng/mL, illustrating diagnostic challenges and management.

Use Cases

• Analyze quantitative CT enhancement values (arterial, portal, delayed phases) to characterize hypervascular phenotype in rare gastric cancers.
• Correlate markedly elevated serum AFP levels (918.88 ng/mL) with clinical outcomes like liver metastasis in hepatoid adenocarcinoma.
• Study the diagnostic framework proposed for differentiating hepatoid adenocarcinoma from hepatocellular carcinoma using case-specific imaging and biomarker data.

Strengths

• Includes specific quantitative imaging metrics: CT enhancement values of 52 ± 3 HU (arterial), 78 ± 5 HU (portal), and 85 ± 4 HU (delayed).
• Reports precise serum biomarker level: AFP measured at 918.88 ng/mL.
• Case report provides detailed clinical timeline from diagnosis through postoperative follow-up.

Limitations

• Single-patient case report with no row or column count, limiting statistical analysis.
• Data scope is extremely limited (18.8 KB DOCX file), representing one clinical instance.
• Focus on a specific, rare cancer subtype reduces generalizability to broader oncology datasets.

Provenance

Source

Shi-Yu Zhong via figshare.

Collection Method

Clinical case documentation from patient diagnosis and treatment.

Time Range

Covers patient presentation, treatment, and three-month postoperative follow-up.

Freshness

Last updated March 25, 2026.

Geography

null